Deep Intelligent Pharma Secures $60M in New Funding to Advance AGI for Drug Development

Text｜Hu Xiangyun

Editor｜Hai Ruojing

36Kr learned that the AI pharmaceutical unicorn companyDeep Intelligent PharmaRecently, a new round of financing worth 60 million US dollars has been completed. The new investors in this round of financing include中信资本 (Trustar Capital), 金镒资本 (Jinyi Capital), and 凯泰资本 (Caital Capital). Existing shareholders 鼎晖百孚 (CDH BF Capital) and 新鼎资本 (New Ding Capital) continued to increase their investment, and 指数资本 (Index Capital) continued to serve as the exclusive financial advisor. The funds raised will be mainly used for the upgrading of the core technology system.

Notably, in December last year, Deep Intelligent Pharma just announced a $50 million D-round financing. Within a short span of two months, the company has already secured over $100 million in funding.

Currently, limited by technical capabilities and other factors, most companies still primarily apply AI in the preclinical stage of the new drug development process. In contrast, Deep Intelligent Pharma can provide global pharmaceutical companies with an all-stack intelligent solution covering everything from preclinical research, regulatory submission, clinical trials, to post-marketing studies. According to Deep Intelligent Pharma, in past collaboration cases, the clinical trial protocols written by the company's AI "brain" have achieved "zero revisions," passing regulatory approval on the first attempt.

In the pharmaceutical industry, in the past, the market was often more willing to pay for pipeline assets with certain value and held a more cautious attitude towards pure technology platforms. The breakthrough achieved by Deep Intelligent Pharma in its underlying technical architecture might also be the reason why it has successively gained recognition from investment institutions. Specifically:

First, in terms of the new drug R&D process, Deep Intelligent Pharma no longer focuses on single-function replacements. Instead, it proposes the "Electronic Neuron Single-Point Ineffectiveness Theory." Based on a deep understanding of brain science, Deep Intelligent Pharma cultivates AI into an "autonomous team of digital scientists with 'awareness' in specialized fields." Through decentralized collaboration and self-evolution of the "bionic brain," it builds a cluster of autonomous AI agents capable of completing the entire clinical trial process with ultra-high precision and greater efficiency.

The traditional clinical R&D process includes multiple stages such as registration submission, trial design, clinical operations, and data management. Deep Intelligent Pharma has chosen to transform this complex clinical medical logic into a "bionic brain" constructed from high-precision "Atomic Agents" in the tens of thousands. This includes the Protocol Agent (responsible for top-level design), the Statistical Agent (executing precise calculations), the Regulatory Agent (ensuring compliance), and more.

When executing actual clinical development tasks, the "bionic brain" reaches the level of top scientists through a profound assumption-verification-reflection-correction closed loop for basic specific micro-tasks (data provided by Deep Intelligent Pharma shows that the system's medical terminology accuracy exceeds 99%); moreover, dynamic collaborative network connections have been achieved among Agents.

For example, the Planning Agent and Validation Agent can perform a unique "Planning-Execution Bidirectional Verification," eliminating logical loopholes at the source through cross-validation between the design and execution ends to ensure the scientific nature and feasibility of the plan.

The agent can imitate the human thinking process while performing tasks, conducting self-reflection, learning, and improvement, which is also a major highlight of the Deep Intelligent Pharma technology platform.

Based on a profound understanding of brain science, the system will automatically trigger relevant "reflection" processes to complete attribution analysis (independently determining whether it is due to a lack of knowledge or logical fallacy), traceability positioning (precisely locating the specific agent or decision node), and self-rewriting (the system can autonomously rewrite, differentiate, and restructure agents). In other words, as the usage frequency increases, the system's own existing issues will also be continuously self-corrected.

In addition, to address the hallucination issues when AI models handle serious medical scenarios, Deep Intelligent Pharma has established a four-layer protection mechanism involving training, inference, cross-validation, and post-processing. According to data provided by the company, it has "increased the industrial-grade accuracy of AI to 99.9%, essentially overcoming the hallucination problem."

Notably, based on the current technology platform, Deep Intelligent Pharma has now launched a new Protocol Rehearsal (Intelligent Agent for Trial Simulation). Its function is to conduct a "virtual clinical trial" before human patient enrollment by using AI to simulate potential outcomes in actual clinical trials. This allows for precise prediction of enrollment rates, dropout risks, and resource bottlenecks. This innovation is expected to accelerate the implementation of AI technology in the human clinical trial phase, transforming new drug development from a labor-intensive industry into an autonomous, intelligent decision-making intensive industry.

Investor Perspective

Zhao Lei, Partner of Trustar Capital, stated that the investment in Deep Intelligent Pharma is based on our firm belief in the long-term structural trend of AI empowering clinical CROs. As an industry-leading AI-native company, Deep Intelligent Pharma’s AI capabilities are iterating rapidly, and its Multi-Agent collaboration ability is profoundly transforming the industry’s cost structure and operational model, forming the company’s strongest competitive moat. As a long-term partner, Trustar Capital will leverage its extensive healthcare industry resources and post-investment empowerment experience to help Deep Intelligent Pharma build a sustainable leading edge in technological iteration and global market expansion.

Hui Li, founder and managing partner of Gold Yili Capital, stated that AI is driving a new wave of productivity revolution worldwide. Deep Intelligent Pharma, as a globally leading AI-driven drug discovery platform, provides innovative pharmaceutical companies with an end-to-end intelligent solution covering preclinical research, regulatory submissions, clinical trials, and post-marketing studies, achieving automation and intelligence across the entire clinical process. This helps pharmaceutical companies reduce costs, improve efficiency, and accelerate drug development. The company itself has achieved rapid commercialization and profitability, becoming a core force in transforming pharmaceutical R&D from labor-intensive to intelligence-intensive. In the AI era, it is quickly disrupting the traditional human-centric paradigm of innovative drug R&D and realizing a new paradigm of intelligent leapfrogging. We are optimistic about the enormous growth potential of Deep Intelligent Pharma in the AI + healthcare field and look forward to collaborating with Deep Intelligent Pharma in the future to jointly build a new global leader in the AI pharmaceuticals industry and usher in a new era of intelligent healthcare.

Vice President of Kaitai Capital, Zhao Tianjun, stated, "AI is the medium of the future." The value of Deep Intelligent Pharma lies not only in applying AI to various aspects of clinical research and development but also in fundamentally changing the decision-making logic and execution paradigm of clinical trials through its self-evolving intelligent system. The company has built an ecosystem of intelligent agents with continuous learning and reflection capabilities, transforming traditional experience- and labor-dependent R&D processes into a new model centered on precise prediction and intelligent collaboration. We are particularly optimistic about its ability to drive the industry's leap from "process optimization" to "process reengineering," which represents not just an improvement in efficiency but also an iteration of the R&D paradigm. Kaitai Capital looks forward to and supports Deep Intelligent Pharma as a key innovator, continuously leading the evolution of clinical R&D into a new stage driven by intelligence.